Rosen Hugh, Sanna Germana, Alfonso Christopher
Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Immunol Rev. 2003 Oct;195:160-77. doi: 10.1034/j.1600-065x.2003.00068.x.
Blood lymphocyte numbers, which are maintained by recirculation through secondary lymphoid organs, are essential for the efficient development of immune responses. Recirculating populations of B and T lymphocytes are regulated by the sphingosine-1-phosphate (S1P) receptor-dependent control of lymphocyte egress. T-cell egress from thymus into blood, egress from lymph node and Peyer's patch into lymph, and B-cell egress into lymph are rapidly and completely inhibited by agonism of S1P receptors. Mesenteric lymph nodes show log-jamming of lymphocytes subjacent to sinus-lining endothelium. Agonism of S1P receptors produces rapid peripheral blood lymphopenia, which is maintained in the presence of receptor agonist. Effector CD4+ and CD8+ T cells, produced by clonal expansion in draining lymph node in response to antigen, are sequestered in lymph node and fail to reach the peripheral blood. The S1P receptor system may represent an early physiological link between the non-specific inflammatory response and the alteration of lymphocyte traffic through draining lymph nodes. Pharmacological subversion of the S1P receptor system, through systemic S1P agonist-induced inhibition of lymphocyte egress, suppresses antigenic responses to peripheral, but not to systemically, delivered antigen. This inhibition induces significant immunosuppression in models of transplantation and autoimmune tissue damage that may prove to be of clinical benefit.
血液淋巴细胞数量通过在二级淋巴器官中的再循环得以维持,对于免疫反应的有效发展至关重要。B淋巴细胞和T淋巴细胞的再循环群体受鞘氨醇-1-磷酸(S1P)受体依赖性淋巴细胞流出控制的调节。T细胞从胸腺进入血液、从淋巴结和派尔集合淋巴结进入淋巴以及B细胞进入淋巴均会因S1P受体激动作用而迅速且完全受到抑制。肠系膜淋巴结显示窦内衬内皮下方淋巴细胞的阻塞。S1P受体激动作用会导致外周血淋巴细胞迅速减少,且在存在受体激动剂的情况下持续存在。效应性CD4⁺和CD8⁺T细胞由引流淋巴结中针对抗原的克隆扩增产生,被隔离在淋巴结中,无法到达外周血。S1P受体系统可能代表了非特异性炎症反应与通过引流淋巴结的淋巴细胞运输改变之间的早期生理联系。通过全身性S1P激动剂诱导的淋巴细胞流出抑制对S1P受体系统进行药理学颠覆,可抑制对外周而非全身性递送抗原的抗原反应。这种抑制在移植和自身免疫性组织损伤模型中诱导显著的免疫抑制,这可能证明具有临床益处。